MEDICLIN AG (MED.DE) Stock Fundamental Analysis
FRA:MED - Deutsche Boerse Ag - DE0006595101 - Common Stock - Currency: EUR
MED gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 24 industry peers in the Health Care Providers & Services industry. While MED has a great profitability rating, there are some minor concerns on its financial health. MED scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year MED was profitable.
MED had a positive operating cash flow in the past year.
In multiple years MED reported negative net income over the last 5 years.
MED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MED's Return On Assets of 2.74% is fine compared to the rest of the industry. MED outperforms 66.67% of its industry peers.
MED has a better Return On Equity (11.16%) than 70.83% of its industry peers.
The Return On Invested Capital of MED (5.61%) is better than 66.67% of its industry peers.
MED had an Average Return On Invested Capital over the past 3 years of 3.46%. This is below the industry average of 5.60%.
The last Return On Invested Capital (5.61%) for MED is above the 3 year average (3.46%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.74% | ||
| ROE | 11.16% | ||
| ROIC | 5.61% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
MED has a Profit Margin of 3.25%. This is in the better half of the industry: MED outperforms 70.83% of its industry peers.
In the last couple of years the Profit Margin of MED has grown nicely.
Looking at the Operating Margin, with a value of 6.99%, MED is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
In the last couple of years the Operating Margin of MED has grown nicely.
MED's Gross Margin of 83.13% is amongst the best of the industry. MED outperforms 87.50% of its industry peers.
In the last couple of years the Gross Margin of MED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.99% | ||
| PM (TTM) | 3.25% | ||
| GM | 83.13% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MED is still creating some value.
Compared to 1 year ago, MED has about the same amount of shares outstanding.
MED has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for MED has been reduced compared to a year ago.
2.2 Solvency
MED has an Altman-Z score of 1.61. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.61, MED is in line with its industry, outperforming 58.33% of the companies in the same industry.
The Debt to FCF ratio of MED is 12.94, which is on the high side as it means it would take MED, 12.94 years of fcf income to pay off all of its debts.
MED has a Debt to FCF ratio of 12.94. This is comparable to the rest of the industry: MED outperforms 41.67% of its industry peers.
MED has a Debt/Equity ratio of 1.96. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.96, MED perfoms like the industry average, outperforming 41.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.96 | ||
| Debt/FCF | 12.94 | ||
| Altman-Z | 1.61 |
ROIC/WACC1.19
WACC4.73%
2.3 Liquidity
A Current Ratio of 1.79 indicates that MED should not have too much problems paying its short term obligations.
With an excellent Current ratio value of 1.79, MED belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
MED has a Quick Ratio of 1.75. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
MED has a Quick ratio of 1.75. This is amongst the best in the industry. MED outperforms 95.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.75 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 330.51% over the past year.
The Earnings Per Share has been growing by 20.79% on average over the past years. This is a very strong growth
Looking at the last year, MED shows a decrease in Revenue. The Revenue has decreased by -0.22% in the last year.
Measured over the past years, MED shows a small growth in Revenue. The Revenue has been growing by 2.19% on average per year.
EPS 1Y (TTM)330.51%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%138.17%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%-3.05%
3.2 Future
Based on estimates for the next years, MED will show a small growth in Earnings Per Share. The EPS will grow by 6.48% on average per year.
Based on estimates for the next years, MED will show a small growth in Revenue. The Revenue will grow by 2.80% on average per year.
EPS Next Y20.73%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
EPS Next 5YN/A
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MED is valuated cheaply with a Price/Earnings ratio of 5.73.
Compared to the rest of the industry, the Price/Earnings ratio of MED indicates a rather cheap valuation: MED is cheaper than 91.67% of the companies listed in the same industry.
MED is valuated cheaply when we compare the Price/Earnings ratio to 28.10, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 5.96 indicates a rather cheap valuation of MED.
100.00% of the companies in the same industry are more expensive than MED, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 20.74. MED is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.73 | ||
| Fwd PE | 5.96 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MED is valued cheaply inside the industry as 91.67% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MED indicates a somewhat cheap valuation: MED is cheaper than 79.17% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.95 | ||
| EV/EBITDA | 3.54 |
4.3 Compensation for Growth
MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MED may justify a higher PE ratio.
PEG (NY)0.28
PEG (5Y)0.28
EPS Next 2Y12.62%
EPS Next 3Y6.48%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.37%.
MED's Dividend Yield is a higher than the industry average which is at 2.73.
Compared to an average S&P500 Dividend Yield of 2.43, MED's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.37% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DP0%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
FRA:MED (5/5/2025, 7:00:00 PM)
2.98
+0.02 (+0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners2.09%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap141.55M
Analysts83.33
Price Target4.79 (60.74%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.37% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.44%
PT rev (3m)9.94%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.02%
EPS NY rev (3m)26.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.81%
Revenue NY rev (3m)2.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.73 | ||
| Fwd PE | 5.96 | ||
| P/S | 0.19 | ||
| P/FCF | 3.95 | ||
| P/OCF | 1.76 | ||
| P/B | 0.64 | ||
| P/tB | 0.72 | ||
| EV/EBITDA | 3.54 |
EPS(TTM)0.52
EY17.45%
EPS(NY)0.5
Fwd EY16.78%
FCF(TTM)0.76
FCFY25.35%
OCF(TTM)1.7
OCFY56.92%
SpS16.11
BVpS4.68
TBVpS4.16
PEG (NY)0.28
PEG (5Y)0.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.74% | ||
| ROE | 11.16% | ||
| ROCE | 7.23% | ||
| ROIC | 5.61% | ||
| ROICexc | 7.31% | ||
| ROICexgc | 7.65% | ||
| OM | 6.99% | ||
| PM (TTM) | 3.25% | ||
| GM | 83.13% | ||
| FCFM | 4.69% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexcg growth 3Y64.29%
ROICexcg growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score7
Asset Turnover0.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.96 | ||
| Debt/FCF | 12.94 | ||
| Debt/EBITDA | 4.2 | ||
| Cap/Depr | 88.88% | ||
| Cap/Sales | 5.84% | ||
| Interest Coverage | 2.35 | ||
| Cash Conversion | 77.64% | ||
| Profit Quality | 144.43% | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.75 | ||
| Altman-Z | 1.61 |
F-Score7
WACC4.73%
ROIC/WACC1.19
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)330.51%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%138.17%
EPS Next Y20.73%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%-3.05%
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
EBIT growth 1Y320.43%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year114.46%
EBIT Next 3Y28.07%
EBIT Next 5YN/A
FCF growth 1Y-11.25%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y3.29%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%